Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $64.44

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned a consensus rating of “Buy” from the eleven brokerages that are covering the company, Marketbeat reports. Eleven analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $64.44.

Several brokerages recently issued reports on JSPR. JMP Securities restated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research note on Monday, January 6th. UBS Group initiated coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $38.00 price target on the stock. HC Wainwright decreased their target price on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. BMO Capital Markets started coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price on the stock. Finally, Royal Bank of Canada lowered their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research note on Thursday, January 9th.

Institutional Trading of Jasper Therapeutics

Large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in Jasper Therapeutics during the third quarter worth about $251,000. Samsara BioCapital LLC grew its stake in Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after buying an additional 59,642 shares during the last quarter. Barclays PLC grew its stake in Jasper Therapeutics by 320.7% during the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after buying an additional 12,308 shares during the last quarter. Wellington Management Group LLP bought a new stake in Jasper Therapeutics during the third quarter worth about $447,000. Finally, Ally Bridge Group NY LLC grew its stake in shares of Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after purchasing an additional 180,852 shares during the last quarter. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Stock Performance

NASDAQ:JSPR opened at $5.80 on Thursday. The firm’s 50-day moving average is $10.28 and its 200-day moving average is $16.91. The company has a market cap of $87.01 million, a price-to-earnings ratio of -1.22 and a beta of 2.11. Jasper Therapeutics has a 52-week low of $4.55 and a 52-week high of $31.01.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.